SciVision Biotech Inc. (1786.TW)
TWD 90.3
(-1.85%)
TWD 90.3
(-1.85%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 347.91 Million TWD | -16.38% |
| 2022 | 416.05 Million TWD | -34.52% |
| 2021 | 635.36 Million TWD | 96.3% |
| 2020 | 323.68 Million TWD | 3.31% |
| 2019 | 313.3 Million TWD | -28.45% |
| 2018 | 437.9 Million TWD | -12.5% |
| 2017 | 500.48 Million TWD | 59.97% |
| 2016 | 312.85 Million TWD | 1054.49% |
| 2015 | 27.09 Million TWD | 2406.85% |
| 2014 | 1.08 Million TWD | -76.28% |
| 2013 | 4.55 Million TWD | -18.44% |
| 2012 | 5.58 Million TWD | 148.31% |
| 2011 | 2.25 Million TWD | -86.82% |
| 2010 | 17.07 Million TWD | -54.49% |
| 2009 | 37.5 Million TWD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 323.05 Million TWD | -7.15% |
| 2024 Q2 | 229.58 Million TWD | -28.93% |
| 2023 Q4 | 347.91 Million TWD | -1.02% |
| 2023 Q3 | 351.48 Million TWD | -4.93% |
| 2023 FY | 347.91 Million TWD | -16.38% |
| 2023 Q1 | 381.41 Million TWD | -8.32% |
| 2023 Q2 | 369.71 Million TWD | -3.07% |
| 2022 FY | 416.05 Million TWD | -34.52% |
| 2022 Q4 | 416.05 Million TWD | 26.29% |
| 2022 Q3 | 329.44 Million TWD | 0.13% |
| 2022 Q2 | 329.02 Million TWD | -0.02% |
| 2022 Q1 | 329.09 Million TWD | -48.2% |
| 2021 FY | 635.36 Million TWD | 96.3% |
| 2021 Q2 | 636.71 Million TWD | 0.28% |
| 2021 Q4 | 635.36 Million TWD | -0.74% |
| 2021 Q1 | 634.93 Million TWD | 96.16% |
| 2021 Q3 | 640.09 Million TWD | 0.53% |
| 2020 Q3 | 322.32 Million TWD | 0.46% |
| 2020 FY | 323.68 Million TWD | 3.31% |
| 2020 Q4 | 323.68 Million TWD | 0.42% |
| 2020 Q1 | 314.23 Million TWD | 0.3% |
| 2020 Q2 | 320.84 Million TWD | 2.1% |
| 2019 Q4 | 313.3 Million TWD | 0.24% |
| 2019 Q1 | 312.88 Million TWD | -28.55% |
| 2019 FY | 313.3 Million TWD | -28.45% |
| 2019 Q3 | 312.57 Million TWD | 0.38% |
| 2019 Q2 | 311.37 Million TWD | -0.48% |
| 2018 Q2 | 500.01 Million TWD | 2.45% |
| 2018 Q1 | 488.03 Million TWD | -2.49% |
| 2018 FY | 437.9 Million TWD | -12.5% |
| 2018 Q4 | 437.9 Million TWD | -10.34% |
| 2018 Q3 | 488.4 Million TWD | -2.32% |
| 2017 Q1 | 324.93 Million TWD | 3.86% |
| 2017 Q3 | 527.61 Million TWD | 10.09% |
| 2017 Q4 | 500.48 Million TWD | -5.14% |
| 2017 FY | 500.48 Million TWD | 59.97% |
| 2017 Q2 | 479.23 Million TWD | 47.49% |
| 2016 Q2 | 241.97 Million TWD | 36.31% |
| 2016 Q1 | 177.51 Million TWD | 555.07% |
| 2016 FY | 312.85 Million TWD | 1054.49% |
| 2016 Q3 | 309.66 Million TWD | 27.97% |
| 2016 Q4 | 312.85 Million TWD | 1.03% |
| 2015 Q4 | 27.09 Million TWD | -3.09% |
| 2015 FY | 27.09 Million TWD | 2406.85% |
| 2015 Q3 | 27.96 Million TWD | 808.48% |
| 2015 Q2 | 3.07 Million TWD | 71.57% |
| 2015 Q1 | 1.79 Million TWD | 65.96% |
| 2014 Q3 | 1.46 Million TWD | -63.34% |
| 2014 Q2 | 3.99 Million TWD | 37.45% |
| 2014 Q1 | 2.9 Million TWD | -36.25% |
| 2014 FY | 1.08 Million TWD | -76.28% |
| 2014 Q4 | 1.08 Million TWD | -26.16% |
| 2013 Q4 | 4.55 Million TWD | 132.86% |
| 2013 Q1 | 4.03 Million TWD | -27.85% |
| 2013 FY | 4.55 Million TWD | -18.44% |
| 2013 Q3 | 1.95 Million TWD | -63.75% |
| 2013 Q2 | 5.39 Million TWD | 33.91% |
| 2012 FY | 5.58 Million TWD | 148.31% |
| 2012 Q3 | 3.89 Million TWD | 45.48% |
| 2012 Q2 | 2.67 Million TWD | 0.0% |
| 2012 Q4 | 5.58 Million TWD | 43.4% |
| 2011 Q4 | 2.25 Million TWD | 0.0% |
| 2011 Q2 | 1.9 Million TWD | 0.0% |
| 2011 FY | 2.25 Million TWD | -86.82% |
| 2010 Q4 | 17.07 Million TWD | 0.0% |
| 2010 FY | 17.07 Million TWD | -54.49% |
| 2009 FY | 37.5 Million TWD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 605.96 Million TWD | 42.585% |
| Maxigen Biotech Inc. | 50 Thousand TWD | -695726.0% |
| Bionime Corporation | 2.81 Billion TWD | 87.65% |
| Pegavision Corporation | 1.56 Billion TWD | 77.755% |
| Visco Vision Inc. | 1.08 Billion TWD | 67.898% |